MedTrace Logo

Assess the Effect of Cangrelor at the Therapeutic Dose and a Supratherapeutic Dose Level on the QT/QTc Interval in Healthy Volunteers

NCT00699504 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 67

Last updated 2012-01-18

No results posted yet for this study

Summary

To assess the safety of cangrelor on cardiac repolarization as measured by electrocardiogram (ECG) at therapeutic and supratherapeutic doses.

Conditions

  • Healthy

Interventions

DRUG

cangrelor

IV bolus 60 mcg/kg; 8 mcg/kg x 3 hrs

DRUG

cangrelor

30 mcg/kg bolus; 4 mcg/kg/min x 3 hrs. Oral placebo capsule

DRUG

cangrelor

60 mcg/kg bolus; 8 mcg/kg/min x 3 hrs. Oral placebo capsule

DRUG

moxifloxacin

400 mg orally. Placebo IV bolus and infusion.

DRUG

placebo

placebo IV and oral

Sponsors & Collaborators

  • The Medicines Company

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Masking
TRIPLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2008-06-30
Primary Completion
2008-11-30
Completion
2008-11-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00699504 on ClinicalTrials.gov